BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

726 related articles for article (PubMed ID: 9406695)

  • 21. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
    Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
    Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma.
    Rufini V; Castaldi P; Treglia G; Perotti G; Gross MD; Al-Nahhas A; Rubello D
    Biomed Pharmacother; 2008 Mar; 62(3):139-46. PubMed ID: 17892924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indium-111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma.
    Kurtaran A; Scheuba C; Kaserer K; Schima W; Czerny C; Angelberger P; Niederle B; Virgolini I
    J Nucl Med; 1998 Nov; 39(11):1907-9. PubMed ID: 9829581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
    Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P
    J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 111In-pentetreotide scintigraphy in the post-thyroidectomy follow-up of patients with medullary thyroid carcinoma.
    Celentano L; Sullo P; Klain M; Lupoli G; Cascone E; Salvatore M
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):131-3. PubMed ID: 9002771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
    Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G
    Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.
    Brandt-Mainz K; Müller SP; Görges R; Saller B; Bockisch A
    Eur J Nucl Med; 2000 May; 27(5):490-6. PubMed ID: 10853802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
    Juweid ME; Hajjar G; Swayne LC; Sharkey RM; Suleiman S; Herskovic T; Pereira M; Rubin AD; Goldenberg DM
    Cancer; 1999 Apr; 85(8):1828-42. PubMed ID: 10223579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies.
    Juweid M; Sharkey RM; Behr T; Swayne LC; Herskovic T; Pereira M; Rubin AD; Hanley D; Dunn R; Siegel J; Goldenberg DM
    J Nucl Med; 1996 Jun; 37(6):905-11. PubMed ID: 8683309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
    Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
    Chen SW; Chen YK
    World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo somatostatin receptor imaging in medullary thyroid carcinoma.
    Kwekkeboom DJ; Reubi JC; Lamberts SW; Bruining HA; Mulder AH; Oei HY; Krenning EP
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1413-7. PubMed ID: 8501144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic utility of PET/CT with
    Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rare presentation of occult medullary carcinoma of the thyroid as a mediastinal mass.
    Daraki V; Koukouraki S; Velegrakis G; Mamalaki E; Haniotis VT; Kalikakis G; Stathaki MI; Karkavitsas N; Papavasiliou SS
    Hormones (Athens); 2012; 11(2):210-4. PubMed ID: 22801569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiolabeled somatostatin analog scintigraphy in medullary thyroid carcinoma and carcinoid tumor.
    Rufini V; Salvatori M; Saletnich I; Valenza V; Maussier ML; Martino G; Corsello SM; Pantusa M; Casolo A; Troncone L
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):140-4. PubMed ID: 9002774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Somatostatin receptor imaging in persistent medullary thyroid carcinoma.
    Frank-Raue K; Bihl H; Dörr U; Buhr H; Ziegler R; Raue F
    Clin Endocrinol (Oxf); 1995 Jan; 42(1):31-7. PubMed ID: 7889629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The therapeutic value of SST-A octreotide alone or with adjuvant treatment in patients with advanced medullary thyroid carcinoma and positive (111)In-octreotide scan.
    Vainas I; Drimonitis A; Boudina M; Kaprara A; Iakovou I; Salem N; Koussis C
    Hell J Nucl Med; 2005; 8(1):43-7. PubMed ID: 15886753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma.
    Vainas I; Koussis Ch; Pazaitou-Panayiotou K; Drimonitis A; Chrisoulidou A; Iakovou I; Boudina M; Kaprara A; Maladaki A
    J Exp Clin Cancer Res; 2004 Dec; 23(4):549-59. PubMed ID: 15743023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation.
    Koopmans KP; de Groot JW; Plukker JT; de Vries EG; Kema IP; Sluiter WJ; Jager PL; Links TP
    J Nucl Med; 2008 Apr; 49(4):524-31. PubMed ID: 18375923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.